Real‐world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database
Diabetes, Obesity and Metabolism · 2025-05 · 27 (5) · 2810-2821
DOI: 10.1111/dom.16290 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 25.02.2025. Verfasst von Emily R Hankosky und 6 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Tirzepatide, Hypoglycemic Agents, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To understand real‐world tirzepatide utilization and effectiveness (change in weight and body mass index [BMI]) among people without type 2 diabetes (T2D) in the United States. Materials and Methods This retrospective, observational study used Optum's de‐identified Market Clarity database (index date: first‐observed tirzepatide claim; index period: 13 May 2022–30 September 2023). Outcomes were assessed in 3 cohorts: (1) Overall cohort: age ≥18 years; ≥1 tirzepatide claim; no baseline T2D diagnosis codes, anti‐diabetes medication use (except metformin) or glycated haemoglobin ≥6.5%; continuous medical and pharmacy enrolment for ≥12 months pre‐index. (2) Utilization cohort: all above criteria and anti‐obesity medication (AOM)‐eligible individuals (BMI ≥30 kg/m 2 , or ≥27 kg/m 2 with ≥1 obesity‐related complication [ORC]) for assessment of tirzepatide utilization (persistence, discontinuation, dose escalation and switching 6 months post‐index). (3) Effectiveness cohort: all above criteria and AOM‐eligible glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA)‐naive individuals persistent on tirzepatide for ≥6 months with pre‐ and post‐index weight and BMI measurements for assessment of tirzepatide effectiveness (mean absolute and percent bodyweight/BMI change from baseline and bodyweight/BMI reduction ≥5%, ≥10%, ≥15% and ≥20%). All analyses were descriptive.
Results
Overall cohort included 20,998 individuals (mean age: 47.4 years, female: 74.9%, mean BMI: 36.9 kg/m 2 ). At index, 66.0% of individuals had ≥1 ORC, while 44.4% had ≥2 ORCs. Persistence in the utilization cohort was 55.4%; 30.8% switched to a different AOM/GLP‐1 RA analogue or restarted tirzepatide after discontinuation, and by the sixth prescription fill, 74.2% were on
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Tigermed-BDM, Somerset, New Jersey, USA.
ORCID-Profile: Emily R Hankosky, Theresa Hunter Gibble
Förderung
- Eli Lilly and Company
Zitieren
APA
Hankosky, E. R., Chinthammit, C., Meeks, A., Huang, A., Ward, J. M., Mojdami, D., & Gibble, T. H. (2025). Real‐world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database. Diabetes, Obesity and Metabolism, 27(5), 2810-2821. https://doi.org/10.1111/dom.16290
Vancouver
Hankosky ER, Chinthammit C, Meeks A, Huang A, Ward JM, Mojdami D, et al. Real‐world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database. Diabetes, Obesity and Metabolism. 2025;27(5):2810-2821. doi:10.1111/dom.16290
BibTeX
@article{Hankosky2025,
author = {Hankosky, Emily R and Chinthammit, Chanadda and Meeks, Alexandra and Huang, Ahong and Ward, Jennifer M and Mojdami, Donna and Gibble, Theresa Hunter},
title = {Real‐world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {5},
pages = {2810--2821},
doi = {10.1111/dom.16290}
}
EUVIMED